Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 7, 2010, Pages 788-794

  Whitton, Peter S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Exenatide; inflammation; minocycline; neuroinflammation; NSAID; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SYNUCLEIN; CELECOXIB; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELOXICAM; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB; ANTIINFLAMMATORY AGENT;

BLOOD BRAIN BARRIER; ENCEPHALITIS; HUMAN; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; NERVE CELL; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; NEURONS; PARKINSON DISEASE;

EID: 77954127252     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Deumens R, Blokland A, Prickaerts J: Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol (2002) 175(2):303-317.
2. Gwinn-Hardy K: Genetics of parkinsonism. Mov Discord (2002) 17(4):645-656.
3. Schapira AH: Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal. Mov Discord (1994) 9(2):125-138.
4. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality. 1967. Neurology (1998) 50(2):318.
5. Jenner P: Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci (2001) 24(5):245-247.
6. McGeer PL, Yasojima K, McGeer EG: Inflammation in Parkinson's disease. Adv Neurol (2001) 86:83-89.
7. Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 150(8):963-976.
8. Kim SU, de Vellis J: Microglia in health and disease. J Neurosci Res (2005) 81(3):302-313.
9. Beyer M, Gimsa U, Eyüpoglu IY, Hailer NP, Nitsch R: Phagocytosis of neuronal or glial debris by microglial cells: Upregulation of MHC class II expression and multinuclear giant cell formation in vitro. Glia (2000) 31(3):262-266.
10. Wojtera M, Sikorska B, Sobow T, Liberski PP: Microglial cells in neurodegenerative disorders. Folia Neuropathol (2005) 43(4): 311-321.
11. McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol (1988) 24(4):574-576.
12. Aloisi F: Immune function of microglia. Glia (2001) 36(2): 165-179.
13. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol (2005) 76(2):77-98.
14. Tansey MG, Goldberg MS: Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (2010) 37(3):510-518.
15. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 38(8):1285-1291.
16. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T: Interleukin-1 β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 180(2):147-150.
17. Rowe DB, Le W, Smith RG, Appel SH: Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res (1998) 53(5):551-558.
18. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P: Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 202(1-2): 17-20.
19. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T: Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm (2000) 107(3): 335-341.
20. Müller T, Blum-Degen D, Przuntek H, Kuhn W: Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand (1998) 98(2):142-144.
21. Knott C, Stern G, Wilkin GP: Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci (2000) 16(6):724-739.
22. Nagatsu T, Mogi M, Ichinose H, Togari A: Cytokines in Parkinson's disease. J Neural Transm Suppl (2000) (58):143-151.
23. Nagatsu T: Parkinson's disease: Changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm (2002) 109(5-6):731-745.
24. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol (2009) 8(4): 382-397.
25. Orr CF, Rowe DB, Halliday GM: An inflammatory review of Parkinson's disease. Prog Neurobiol (2002) 68(5):325-340.
26. Griffin WS, Liu L, Li Y, Mrak RE, Barger SW: Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation (2006) 3:5.
27. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ: Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2008) 29(11):1690-1701.
28. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ: Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA (2009) 106(33):14063-14068.
29. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J: Aggregated α-synuclein activates microglia: A process leading to disease progression in Parkinson's disease. FASEB J (2005) 19(6):533-542.
30. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL: Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol (2006) 197(2):275-283.
31. Tansey MG, Wyss-Coray T: Cytokines in CNS inflammation and disease. In: Central nervous system diseases and inflammation. Lane TE, Carson M, Bergmann C, Wyss-Coray T (Eds), 1st Edition, Springer, New York, NY, USA (2008):59-106.
32. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem (2002) 81(6):1285-1297.
33. Gao HM, Liu B, Zhang W, Hong JS: Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease. FASEB J (2003) 17(13):1957-1959.
34. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci (2000) 20(16):6309-6316.
35. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA: Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol (1994) 17(4):370-379.
36. Wu XF, Block ML, Zhang W, Qin L, Wilson B, Zhang WQ, Veronesi B, Hong JS: The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal (2005) 7(5-6):654-661.
37. McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 10(Suppl 1):S3-S7.
38. Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H: Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice. J Biol Chem (2004) 279(49):51647-51653.
39. Lucas SM, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 147(Suppl 1):S232-S240.
40. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C et al: Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2009) 119(1):182-192.
41. Prat A, Biernacki K, Wosik K, Antel JP: Glial cell influence on the human blood-brain barrier. Glia (2001) 36(2):145-155.
42. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD: 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci (2005) 22(5):1158-1168.
43. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH: Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 57(2):176-179. (Pubitemid 40179854)
44. Bohatschek M, Werner A, Raivich G: Systemic LPS injection leads to granulocyte influx into normal and injured brain: Effects of ICAM-1 deficiency. Exp Neurol (2001) 172(1):137-152.
45. Herrera AJ, Tomás-Camardiel M, Venero JL, Cano J, Machado A: Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J Neural Transm (2005) 112(1):111-119.
46. Simard AR, Rivest S: Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J (2004) 18(9): 998-1000.
47. Kokovay E, Cunningham LA: Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol Dis (2005) 19(3):471-478.
48. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, van Oostrom JC, Portman A, Leenders KL: Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (2008) 115(7):1001-1009.
49. Gao HM, Liu B, Zhang W, Hong JS: Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci (2003) 24(8):395-401.
50. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N: Neuroprotective effects of non-steroidal antiinflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem (2001) 76(6):1895-1904.
51. Sairam K, Saeavanan KS, Banergee R, Mohanarkumar KP: Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res (2003) 966(2):245-252.
52. Teissmann P, Ferger B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 39(2):167-174.
53. Przybyłkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Członkowska A, Członkowski A: Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res (2004) 1019(1-2):144-151.
54. Sánchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O: Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1(1):6.
55. +: Differential requirement for neuronal cyclooxygenase activity. J Neurosci Res (2005) 81(1):121-131.
56. Wang M.J, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Jeng K-CG: Silymarin protects dopaminergic neurons against lipopolysacchride-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci (2002) 16(11):2103-2112.
57. Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E: Aspirin protects striatal dopaminergic neurons from neurotoxin-induced damage: An in vivo microdialysis study. Brain Res (2006) 1095(1):167-177. (Pubitemid 43884742)
58. +/MPTP toxicity in vitro and in vivo. Neurochem Res (2009) 34(2):304-310.
59. Gupta A, Dhir A, Kumar A, Kulkami SK: Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacol Biochem Behav (2009) 94(2):219-226.
60. Sui Y, Stanić D, Tomas D, Jarrott B, Horne MK: Meloxicam reduces lipopolysaccharide-induced degeneration of dopaminergic neurons in the rat substantia nigra pars compacta. Neurosci Letts (2009) 460(2):121-125.
61. Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 60(8):1059-1064.
62. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann Neurol (2005) 58(6): 963-967. (Pubitemid 41746889)
63. Hald A, Lotharious J: Oxidative stress and inflammation in Parkinson's disease: Is there a causal link? Exp Neurol (2005) 193(2):279-290.
64. Samii A, Etminan M, Wiens MO, Jafari S: NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging (2009) 26(9):769-779.
65. Gören B, Mimbay Z, Bilici N, Zarifoǧlu M, Oǧul E, Korfali E: Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model. Turk Neurosurg (2009) 19(3):230-236.
66. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK: Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol (2007) 64(4):576-580.
67. Hernán MA, Logroscino G, García Rodríguez LA: Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 66(7):1097-1099.
68. LeWitt PA, Taylor DC: Protection against Parkinson's disease progression: Clinical experience. Neurotherapeutics (2008) 5(2):210-225.
69. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res (2009) 196(2):168-179.
70. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S et al: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA (2001) 98(25):14669-14674.
71. He Y, Appel S, Le W: Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res (2001) 909(1-2):187-193.
72. Quintero EM, Willis L, Singleton R Harris N, Huang P, Bhat N, Grantholm AC: Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2006) 1093(1):198-207.
73. Diguet E, Gross CE, Tison F, Bezard E: Rise and fall of minocycline in neuroprotection: Need to promote publication of negative results. Exp Neurol (2004) 189(1):1-4.
74. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS: Minocyline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res (2003) 74(2):278-285.
75. NINDS NET-PD Investigators: A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol (2008) 31(3):141-150.
76. Boger HA, Granholm AC, McGinty JF, Middaugh LD: A dual-hit animal model for age-related Parkinsonism. Prog Neurobiol (2010) 90(2):217-229.
77. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, Perez-Alvarez S, de Mera RM, Jordan MJ, Aguirre N, Galindo MF, Villalobos C et al: Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol (2010) 79(2):239-250.
78. Radad K, Moldzio R, Rausch WD: Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can J Neurol Sci (2010) 37(1):81-85.
79. Harkavyi A, Whitton PS: Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Brit J Pharmacol (2010) 159(3):495-501.
80. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs, CS, Whitton PW: Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation (2008) 5:19.
81. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Rönnholm H, Wikström L: Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res (2008) 86(2):326-338.
82. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A et al: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA (2009) 106(4):1285-1290.
83. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J: Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci Res (2006) 55(4):352-360.
84. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem (2003) 278(1):471-478.
85. Dozier DC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP: Glucagon-like peptde-1 protects mesenteric endothelium from injury during inflammation. Peptides (2009) 30(9):1735-1741.
86. Kim S, Moon M, Park S: Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol (2009) 202(3):431-439.
87. De León DD, Crutchlow MF, Ham JY, Stoffers DA: Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol (2006) 38(5-6):845-859.
88. Golde TE: The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Mol Neurodegener (2009) 4:8.